Sort   by:  
 Page size 
UnknownThe Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients.
Not available
S-EPMC6364099 | biostudies-literature
UnknownALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
Not available
S-EPMC4367701 | biostudies-literature
UnknownCD26 as a potential therapeutic target for lung adenocarcinoma.
Not available
S-EPMC12711487 | biostudies-literature
UnknownGenomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer.
Not available
S-EPMC6051154 | biostudies-literature
UnknownIdentification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array.
Not available
S-EPMC2788252 | biostudies-literature
ProteomicsProteomics in mutant KRAS Lung cancer
Proteomic studies to check the effect of MEK1/2 and KRAS G12C inhibitors in lung cancer cells
ORGANISM(S): Homo sapiens (Human) 
2023-08-22 | PXD024023 | Pride
Lung Proteomics Kras 
UnknownA novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer.
Not available
S-EPMC10569300 | biostudies-literature
UnknownImpact on the Nutritional Status and Inflammation of Patients with Cancer Hospitalized after the SARS-CoV-2 Lockdown.
Not available
S-EPMC9268830 | biostudies-literature
UnknownRole of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis.
Not available
S-EPMC3245993 | biostudies-literature
UnknownTrametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Not available
S-EPMC11031964 | biostudies-literature
Sort   by:  
 Page size